Novel treatments may be on the horizon for the advanced form of age-related macular degeneration.
AMD
Latest News
Advertisement
CME Content
Advertisement
The state of retina therapeutics, dissected by international panel
Published: | Updated:
Ophthalmologists face challenges of drug delivery for retinal diseases.
Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
The impact of the COVID-19 pandemic on the management of patients with retinal disorders and considerations for how new practices may be adopted into future practice.
Option detects treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration.
Findings from the Archway trial showed that the PDS effect is long-lasting, consistent, and comparable to those seen with monthly injections.
Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.
Considerations for treating retinal disorders with sustained-release drug delivery implants in an effort to address current treatment challenges in the field.
Dexamethasone rebuttal: Who should perform intravitreal injections?
Published: | Updated:
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
An overview of delivery systems under investigation for retinal disorders and implications for future use.
A discussion highlighting new agents under investigation for retinal disorders and implications for future use based on data revealed in more recent clinical trials.
Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.
Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
Types of delivery methods currently being explored to improve treatment for patients with retinal disorders.
Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.
Challenges associated with delivering therapies currently available to treat retinal disorders and methods being explored to improve drug delivery to patients.
Why investigators are considering AMD to be a disease spectrum rather than a single disease.
Drawbacks and challenges associated with the administration of anti-VEGF injections currently available to treat retinal diseases.
Dr Mariya Moosajee highlights therapies approved as well as under study to improve treatment for patients with inherited retinal disease.
Promoting Tie2 signaling activity may complement inhibition of VEGF in addressing pathology in disease states characterized by angiogenesis, vascular permeability, and inflammation.
Trial shows treatment has acceptable safety profile, may improve visual function.
A discussion regarding the roles of various treatments available for diabetic macular edema and considerations for selecting and sequencing therapy.
An overview of the current treatment landscape for age-related macular degeneration and factors that impact treatment selection.
Types of tests and criteria that can be used to diagnose conditions such as age-related macular degeneration, diabetic macular edema, and inherited retinal disease.